Atara Biotherapeutics Inc
(NAS:ATRA)
$
10.28
-1.35 (-11.61%)
Market Cap: 58.33 Mil
Enterprise Value: 83.40 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 40/100 Atara Biotherapeutics Inc at HC Wainwright Cell Therapy Virtual Conference Transcript
Feb 28, 2023 / 08:00PM GMT
Release Date Price:
$101.25
(-0.74%)
Robert Burns
H.C. Wainwright & Co., LLC - Managing Director, Biotech Equity Research
Thank you for joining our next fireside chat. I'm Robert Burns, the Managing Director and Senior Biotech Analyst at H.C. Wainwright. And I'm joined by Pascal Touchon, the President and CEO of Atara Biotherapeutics. Pascal, thank you for joining us today.
Pascal Touchon
Atara Biotherapeutics - President and Chief Executive Officer
Thank you, Robert. Pleasure to be with you today.
Robert Burns
H.C. Wainwright & Co., LLC - Managing Director, Biotech Equity Research
So for those who may be unfamiliar with the Atara story, can you provide a brief high-level overview of the company's platform and pipeline?
Pascal Touchon
Atara Biotherapeutics - President and Chief Executive Officer
Yes, certainly. So Atara is a company based in California with about 330, 350 staff, and we are a leader in the field of allogeneic T-cell therapy for cancer and (inaudible). In fact, what we're doing at
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot